We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Geron Corp.
GERN 2.080-8.0%Mar 4 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Savant11/29/2011 11:18:51 AM
  Read Replies (1) of 3554
Research from BioMed Tracker and BIO claims that the cancer drug success rate is
a mere 4.7 percent. Upon revealing the study, the agency's Oncologic Drugs
Advisory Committee endorsed several FDA proposals for tightening the accelerated
approval standards.

Studies from the Friends of Cancer Research advocacy group find that new cancer
drugs are approved in just six months on average in the United States -- half the
time it takes for the same drugs to be approved in Europe. "When we realized we
were correct, we thought, 'No one is going to believe us because this goes
against urban legend,'" said Ellen V. Sigal, chairwoman and founder of Friends of
Cancer Research.

User fees from the Prescription Drug User Fee Act of 1992 have helped provide the
FDA with resources to shorten drug review times. The Act is up for
reauthorization next year, and the Friends of Cancer Research argue that the
speed of drug review times might not be as high a priority as achieving other
objectives in advance regulatory science.

* I suppose from a business standpoint, switching the focus to cancer drugs makes sense, but it's a pity, for those in need, that stem cell research could help.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext